3-Chloro-2-methoxy-6-methylpyridine | 1227581-07-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Chloro-2-methoxy-6-methylpyridine
• CAS: 1227581-07-8
• 化学式: C₇H₈ClNO
• 分子量: 157.6
• InChiKey: IXLVEJGDYMDMFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] COMPOSÉS 6,7-DIHYDROPYRAZOLO[1,5-A] PYRAZIN-4(5H)-ONE ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES NÉGATIFS DES RÉCEPTEURS MGLUR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016016395A1

  公开（公告）日：2016-02-04

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

  本发明涉及新型的6,7-二氢吡唑[1,5-a]吡嗪-4(5H)-酮衍生物，作为代谢型谷氨酸受体2型("mGluR2")的负变构调节剂(NAMs)。该发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的方法，以及使用这些化合物和组合物预防或治疗涉及代谢型受体mGluR2亚型的疾病。
• [EN] INHIBITORS OF CBL-B AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE CBL-B ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2019148005A1

  公开（公告）日：2019-08-01

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

  揭示了用于抑制泛素蛋白酶体途径中的E3酶Cbl-b的化合物、组合物和使用方法。这些化合物、组合物和方法可用于调节免疫系统，治疗适合免疫系统调节的疾病，并用于体内、体外或体外细胞的治疗。
• Heterocyclic urea derivatives for the treatment of pain
  申请人：Moss Frederick Stephen

  公开号：US20070117820A1

  公开（公告）日：2007-05-24

  Compounds of formula (I): or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein: P, P′, R 1 , R 2 , n, p, q, r, and s are as defined in the specification, processes for preparing such compounds, pharmaceutical compositions comprising such compounds and their use in therapy.

  式(I)的化合物：或其药学上可接受的盐，或其溶剂化物，其中：P、P'、R1、R2、n、p、q、r和s如规范中所定义，制备这种化合物的过程，包括这种化合物的药物组合物以及它们在治疗中的用途。
• TRIAZOLE DERIVATIVE OR A SALT THEREOF
  申请人：Yoshimura Seiji

  公开号：US20090082367A1

  公开（公告）日：2009-03-26

  [Problem] To provide a compound which may be used in treating diseases in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, especially diabetes and insulin resistance. [Means for Solution] It was found that a triazole derivative or a pharmaceutically acceptable salt thereof, in which the 3-position of triazole ring is substituted with a trisubstituted methyl group and the 5-position is substituted with a lower alkyl, cycloalkyl or the like, has a strong 11β-HSD1-inhibitory activity. In addition, since the triazole derivative of the present invention shows excellent blood glucose-lowering action, it may be used in the treatment of diabetes and insulin resistance.

  [问题] 提供一种可用于治疗11β-羟基类固醇脱氢酶1型（11β-HSD1）相关疾病，尤其是糖尿病和胰岛素抵抗的化合物。[解决方案] 发现三唑衍生物或其药学上可接受的盐，其中三唑环的3位被三取代甲基基团取代，5位被较低的烷基，环烷基或类似物取代，具有强烈的11β-HSD1抑制活性。此外，由于本发明的三唑衍生物显示出优异的降低血糖作用，因此可用于治疗糖尿病和胰岛素抵抗。
• TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR
  申请人：NISSAN CHEMICAL INDUSTRIES, LTD.

  公开号：US20150065705A1

  公开（公告）日：2015-03-05

  There is provided a novel triazinone compound that has an excellent T-type voltage-dependent calcium channel inhibitory activity and is specifically useful for treatment of pain. A compound of Formula (I), a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof: where each substituent is defined in detail in the description or claims, for example R 1 is H or C 1-6 alkoxy, etc., each of L 1 and L 2 is independently a single bond or NR 2 , etc., L 3 is C 1-6 alkylene, etc., A is C 6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc., B is C 3-11 cycloalkylene, etc., D is C 6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc.

  提供了一种新型三嗪酮化合物，具有出色的T型电压依赖性钙离子通道抑制活性，并且特别适用于治疗疼痛。化合物式(I)的化合物，其互变异构体，其药学上可接受的盐或其溶剂化物：其中每个取代基在说明或权利要求书中详细定义，例如R1为H或C1-6烷氧基等，每个L1和L2分别独立地为单键或NR2等，L3为C1-6烷基等，A为C6-14芳基或5至10成员杂环芳基，可选地取代等，B为C3-11环烷基等，D为C6-14芳基或5至10成员杂环芳基，可选地取代等。